A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
A phase 1/2 trial of Debio 1562M in acute myeloid leukaemia, run by Debiopharm International SA, now recruiting.
Overview
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML) is a phase 1/2 interventional study registered as NCT06969430 by Debiopharm International SA, with 154 participants planned, started 2025-05-30 and due to reach its primary completion in 2031-11. Interventions recorded: Debio 1562M.
Similar pages
not linked directly; found by shared links- TrialA Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Shares Debiopharm and the tag pipeline.
- TrialMocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialPhase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialClinical Study of U32 in Patients With Acute Myeloid Leukemia
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialAn Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialFirst-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialA Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialPBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS
Shares Acute myeloid leukaemia and the tag pipeline.